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Abstract
Background: Autosomal recessive cerebellar ataxias (ARCA) are a complex group of neurodegenerative disorders
with great genetic and phenotypic heterogeneity, over 30 genes/loci have been associated with more than 20
different clinical forms of ARCA. Genetic heterogeneity combined with highly variable clinical expression of the
cerebellar symptoms and overlapping features complicate furthermore the etiological diagnosis of ARCA. The
determination of the most frequent mutations and corresponding ataxias, as well as particular features specific to a
population, are mandatory to facilitate and speed up the diagnosis process, especially when an appropriate
treatment is available.
Methods: We explored 166 patients (115 families) refered to the neurology units of Algiers central hospitals
(Algeria) with a cerebellar ataxia phenotype segregating as an autosomal recessive pattern of inheritance. Genomic
DNA was extracted from peripheral blood samples and mutational screening was performed by PCR and direct
sequencing or by targeted genomic capture and massive parallel sequencing of 57 genes associated with inherited
cerebellar ataxia phenotypes.
Results: In this work we report the clinical and molecular results obtained on a large cohort of Algerian patients
(110 patients/76 families) with genetically determined autosomal recessive ataxia, representing 9 different types of
ARCA and 23 different mutations, including 6 novel ones. The five most common ARCA in this cohort were
Friedreich ataxia, ataxia with isolated vitamin E deficiency, ataxia with oculomotor apraxia type 2, autosomal
recessive spastic ataxia of Charlevoix-Saguenay and ataxia with oculomotor apraxia type 1.
Conclusion: We report here a large cohort of patients with genetically determined autosomal recessive ataxia and
the first study of the genetic context of ARCA in Algeria. This study showed that in Algerian patients, the two most
common types of ataxia (Friedreich ataxia and ataxia with isolated vitamin E deficiency) coexist with forms that may
be less common or underdiagnosed. To refine the genotype/phenotype correlation in rare and heteregeneous
diseases as autosomal recessive ataxias, more extensive epidemiological investigations and reports are necessary as
well as more accurate and detailed clinical characterizations. The use of standardized clinical and molecular
protocols would thus enable a better knowledge of the different forms of ARCA.
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Background
Inherited cerebellar ataxia is the consequence of an
impairment of the cerebellum, the brainstem and/or
spinocerebellar tracts. Phenotypic manifestations may
include gait-limb ataxia, frequent falls, dysarthria, adia-
dochokinesia, ophthalmological abnormalities and may
also involve other neurological and/or extraneurological
symptoms. Progression of these features lead to the loss
of ambulatory abilities and often to an early death [1, 2].
Although all patterns of inheritance have been described
in hereditary cerebellar ataxia [2, 3], we focused in this
work on the Autosomal Recessive Cerebellar Ataxias
“ARCA” forms because of the consanguineous context
characterizing the Algerian population.
ARCA’s first symptoms usually appear before 25 years
old, despite the fact that late-onset forms have been
described [1], and are considered as one of the most
complex group in neurogenetics with more than 20
different clinical entities and at least 30 associated genes/
loci [4]. Some of these genes are responsible for worldwide
well-known ataxia forms, while others underlie very rare
forms. Among these, some have only been described in an
isolated population or even in one family [4, 5].
Despite the increasing knowledge in the molecular
aspects of ARCA, a significant proportion of patients
remain with unidentified ARCA. In addition to the
genetic heterogeneity of this group of ataxias, there is an
important phenotypic variability in the expression of the
cerebellar impairment. The clinical manifestations are
indeed as varied as the possible underlying mutations.
The heterogeneous expression of these disorders occurs
within unrelated patients as well as between siblings of
the same family and with the same ataxia form. Further-
more, the existence of atypical phenotypes and overlapping
characteristics bring more complexity to the etiological
diagnosis of ARCA. The delineation of the specific clinical
features to each ARCA is in fact under permanent discus-
sion, thus complicating the molecular investigations, but
also make it an absolute necessity.
Despite ARCA’s high physiopathological diversity, some
clinical entities are known to be the most frequent, such
as Friedreich ataxia (FRDA) and ataxia telangiectasia (AT)
in Europe [6–8] or FRDA and AVED in the Algerian
population [9].
Given the great clinical and genotypic heterogeneity,
as well as overlapping features, identification of the most
common mutations and corresponding ataxia forms,
together with the specific clinical features observed in a
particular population, is crucial to facilitate and speed
up the diagnosis process, especially when an appropriate
treatment could be provided.
This work reports the molecular findings and pheno-
typic features of a large cohort of 110 Algerians patients
with autosomal recessive cerebellar ataxia representing 9
different ataxia entities. We also report some novel muta-
tions, additionaly to mutations already described so far.
Methods
Patients selection
We studied 166 patients (115 families) refered to the
neurology units of Algiers central hospitals (Algeria) and
report a cohort of 110 Algerian patients, belonging to 76
families, with identified causal mutations.
All patients studied had cerebellar ataxia phenotypes
with an autosomal recessive pattern of inheritance. The
existence of similar cases among siblings (and/or family
members) were observed in 30 families and a consan-
guineous background were noted for about 80 % of the
families. Whenever possible, affected siblings and other
family members were also analyzed.
Blood samples were obtained for all the patients who
gave informed consent to take part in the study which
was approved by the Ministry of Health, Health Ethic
Committee, Algeria.
Molecular analysis
Genomic DNA was extracted from peripheral blood
samples using QIAamp DNA Mini Kit®.
For all 166 patients, the approach consisted in per-
forming a systematic screening, using PCR and direct
sequencing, of the mutations responsible for the major
forms of ataxia: the (GAA)n expansion in the first intron
of the frataxin gene causing Friedreich ataxia, and the
c.744delA mutation in exon 5 of the TTPA gene which
causes ataxia with isolated vitamin E deficiency.
When these targeted mutations were absent, patients’
DNA was then analyzed by PCR and sequencing of
genes accountable for some other forms of ataxia
(Ataxia with ocular apraxia 1 and 2 “AOA1, AOA2”;
Autosomal recessive spastic ataxia of Charlevoix-Saguenay
“ARSACS”; Polyneuropathy, hearing loss, ataxia, retinitis
pigmentosa, and cataract syndrome “PHARC”; and
Autosomal recessive cerebellar ataxia 2 “ARCA2”) by
taking into account the specific clinical indications,
while not always strictly relying on them because of
the encountered phenotypic heterogeneity, as well as
on the basis of previous reports incriminating these
genes in our population.
Finally, taking advantage of the availability of targeted
genomic capture of 57 genes (responsible for inherited
cerebellar ataxia phenotypes as well as genes associated
with pathologies presenting ataxia as a major and/or only
sign) and massive parallel sequencing using the Agilent
SureSelect kit®, we were able to select 16 of our patients,
taking into account specific clinical indications as well as
more heterogeneous phenotypes. The used strategy was
similar to the one described by Vasli et al. [10].
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Results
Clinical characteristics
Out of 110 patients with identified molecular alterations,
68 had undergone a complete neurologic examination.
Those patients belonged to 52 unrelated families among
which 40 families (55 patients out of 68) were consan-
guineous. 57 patients were males and 53 females. The
sex ratio was not statistically different (1.07). The mean
age at onset for those 68 patients was 11.1 ± 5.97 SD
years and ranged from birth to 35 years old.
The most common onset sign was gait limb ataxia
with unbalance and lack of coordination. Cerebellar
syndrome was a constant feature, although with various
degrees of disability. Most patients had ataxia (unbalance
and limb incoordination) and experienced frequent falls
along with different symptoms like dysmetria and adiado-
chokinesia. Different stages of disability were observed:
most patients were capable of walking without help, some
of them with unilateral or bilateral help, while 3 were
wheelchair-bound at the time of clinical diagnosis. A few
patients had a mild cerebellar syndrome. Table 1 summa-
rizes the clinical data of this cohort of 68 patients. MRI
results were available for 50 out of 68 patients and EMG
examination was performed in 51 patients. Results are
summarized in Table 2.
Otherwise, we noticed that the 56 patients whose diag-
nosis was not clarified, mostly issued from consanguin-
eous families (39 patients), were represented by 30 males
and 26 females (sex ratio of 1.15), a ratio close to the
group of 110 patients with genetic diagnosis. The mean
age at onset was 7.63 ± 8.17 SD years and ranged from
birth to 31 years old, data not statistically different from
the subgroup of patients with genetic diagnosis, while
cerebellar syndrome, from severe to moderate, was al-
ways present. When available, MRI results and EMG
examination showed the same heterogeneous features as
the group of patients with genetic diagnosis, with no
remarkable delineation of particular phenotypic charac-
teristics or additional associated signs. Also, when avail-
able, deficiency of vitamin E, hypoalbuminia, or elevated
AFP, cholesterol or cholestanol levels, could not be
noticed and were in the normal range.
Molecular characteristics and findings
Among the 110 patients issued from 76 Algerian fam-
ilies, consanguinity was present in 76.36 % of patients
(84 patients/56 families) and absent in 18.18 % of
patients (20 patients/15 families), whereas an undeter-
mined inbreeding context could be noted for the
remaining 5.45 % (6 patients/5 families).
We report 23 different molecular alterations, including
6 not as yet described, in 9 different genes responsible
for autosomal recessive cerebellar ataxia forms. In all
but one patient, these mutations were found at the
homozygous state.
The most common mutation was the (GAA)n expan-
sion in the first intron of the FXN (frataxin) gene which
is responsible for the Friedreich ataxia phenotype [11],
present at the homozygous state in 49 (44.54 %) patients
representing 31 (40.79 %) families. 35 of the 49 homozy-
gous patients (22/35 families) belonged to consanguin-
eous families.
In our cohort, 19 patients representing 16 families
were found to be homozygous for the c.744delA muta-
tion in the fifth exon of the TTPA (tocopherol transfer
protein alpha) gene, responsible for ataxia with isolated
vitamin E deficiency [12]. 12/19 patients (9/16 families)
were issued from consanguineous families.
Table 1 Clinical features of a group of Algerian patients with
autosomal recessive ataxia
Features (68 patients) Number of patients (%) or value
Age of onset (mean, range-years) 11.1 ± 5.97 SD (birth-35)
Cerebellar syndrome 68 (100 %)
Onset sign
Gait ataxia 47 (69.12 %)
Gait ataxia, frequent falls 7 (10.29 %)
Gait ataxia, muscle weakness 6 (8.82 %)
Gait ataxia, dysarthria 3 (4.41 %)
Gait ataxia, head tremor 1 (1.47 %)
Head tremor 1 (1.47 %)
Head tremor, dysarthria 1 (1.47 %)
Psychomotor retardation 2 (2.94 %)
Dysarthria 59 (86.76 %)
Nystagmus 37 (54.41 %)
Visual acuity decline 7 (10.29 %)
Spasticity 11 (16.17 %)
Babinski sign 22 (32.35 %)
Dysmophric signs
Scoliosis 11 (16.17 %)
Pes cavus 20 (29.41 %)
Scoliosis, pes cavus 21 (30.88 %)
Scoliosis, flat feet 3 (4.41 %)
Pes cavus, cranio-facial dysmorphy 1 (1.47 %)
None 12 (17.64 %)
Cognitive impairment 6 (8.82 %)
Cardiomyopathy 7 (10.3 %)
Epilepsy (epileptic seizures) 3 (4.41 %)
Oculomotor apraxia 5 (7.35 %)
Hypoacusia 6 (8.82 %)
Head tremor 10 (14.7 %)
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18 patients representing 12 families were homozygous
for different mutations in the SETX (senataxin) gene
responsible for ataxia with oculomotor apraxia 2 (AOA2).
14/18 patients (9/12 families) were consanguineous.
We also report patients with mutations in the follow-
ing genes: SACS (sacsin), APTX (aprataxin), ADCK3
(aarf domain-containing kinase 3), ABHD12 (abhydro-
lase domain-containing protein 12), SYNE1 (synaptic
nuclear envelope protein 1), and SIL1 (SIL1 nucleotide
exchange factor 1), respectively responsible for autosomal
recessive spastic ataxia of Charlevoix-Saguenay (ARSACS),
ataxia with oculomotor apraxia type 1 (AOA1), spino-
cerebellar ataxia, autosomal recessive 9 (SCAR9), poly-
neuropathy, hearing loss, ataxia, retinitis pigmentosa,
and cataract syndrome (PHARC), spinocerebellar ataxia,
autosomal recessive 8 (SCAR8) and Marinesco-Sjögren
syndrome (MSS). These forms were found in less than
10 patients and some of them in a single patient:
- 8 patients belonging to 6 families carried mutations
in the SACS gene.
- 6 patients belonging to 5 families had mutations in
the APTX gene.
- 6 patients belonging to 3 families showed mutations
in the ABHD12 gene.
- 1 patient carried a homozygous mutation in the
SYNE1 gene and another patient was homozygous for
a mutation in the SIL1 gene.
Table 3 summarizes the molecular findings for the
patients/families for which the mutations were identified.
Discussion
The present study is the first description of Algerian pa-
tients with autosomal recessive ataxia and represents the
largest cohort of patients with genetically characterized
ataxia, with 110 Algerian patients (76 families). Table 4
summarizes the clinical features in the patients for the
different forms of ARCA studied. Most patients (76.36 %)
had consanguineous parents, a proportion that might be
higher if we consider distant consanguinity, and all the pa-
tients except one carried mutations at a homozygous state,
a predictable issue if we consider cultural practices of in-
breeding in our population.
Our cohort did not include any ataxia telangiecta-
sia patients, although it is reported to be the second
most common ARCA [6, 13]. Despite the fact that
the gene was included in the panel of genes screened
by targeted genomic capture and high-throughput se-
quencing, no mutations were identified in the Algerian
patients. Indeed, since the diagnosis of ataxia telangi-
ectasia is based primarily on clinical criteria in our
country, we didn’t get samples to analyze as the evok-
ing phenotype of this disease could be sufficient.
Therefore, this form of ataxia could be more common
in Algeria.
However, we were able to report 23 different molecu-
lar alterations, including 6 novel mutations, allowing us
to identify 9 different forms of autosomal recessive cere-
bellar ataxias in our population (Fig. 1). Five forms of
ARCA appear to be most frequent in the Algerian
population.
FRDA patients
We identified 49 patients (31 families) carrying muta-
tions in the FXN gene responsible for Friedreich ataxia
(FRDA) [11], in accordance with epidemiological data
acknowledging Friedreich ataxia as the most common
form of autosomal recessive ataxia in Europe [14]. Even
if rare compound heterozygous mutations, (GAA)n ex-
pansion associated with a point mutation, were de-
scribed in some patients, all our patients carried
exclusively the homozygous unstable trinucleotide repeat
(GAA)n in the first intron of the FXN gene, as reported
in the majority of patients reported worldwide [15].
In our cohort, 26 of the 49 patients had undergone
neurological examination. 24 of them had gait-limb
ataxia as a first sign. Head tremor was the first sign in
one patient, while another patient displayed muscle
weakness.
The age at onset in our cohort ranged from 4 to
35 years old, with a mean onset age of 12.74 ± 7.15 SD
years. Most patients (24) had a classical onset age,
between 4 and 20 years old, while one patient had onset
at 27 and another at 35 years, considering them affected
by late onset forms.
Table 2 Brain MRI and EMG results of a group of Algerian
patients with autosomal recessive ataxia
Imaging and elctrophysiological investigation Number of patients (%)
Brain MRI (50 patients)
Normal 21 (30.88 %)
Cerebellar hemisphere atrophy 14 (20.6 %)
Cerebellar and vermian atrophy 7 (10.3 %)
Vermian atrophy 5 (7.35 %)
Frontoparietal atrophy 1 (1.47 %)
Parietooccipital atrophy 1 (1.47 %)
Spinal cord atrophy 1 (1.47 %)
Unavailable 18 (26.47 %)
Electromyography (EMG) (51 patients)
Demyelinating sensory motor polyneuropathy 24 (35.3 %)
Sensory Neuropathy 15 (22.06 %)
Axonal sensorimotor neuropathy 4 (5.88 %)
Normal 8 (11.76 %)
Unavailable 17 (25 %)
Hamza et al. BMC Medical Genetics Page 4 of 12
Dysarthria, which is considered as a clinical feature in
Friedreich patients [16], was present in 23 patients,
being severe in two of them.
The upper limb tendon reflexes were abolished in 15
patients, were brisk in 3 and normal in 5. At the same
time, lower limb tendon reflexes were abolished in 19
patients, brisk in 4 and normal in one patient. Babinski
sign was noted in 12 patients, as pointed out by previous
reports [14, 17, 18].
In 22 patients, dysmorphic features was either scoliosis
(8 patients), pes cavus (3 patients) or both scoliosis and
pes cavus (11 patients), one patient presented with a
thoracic deformation, according to the progression of
the symptoms in Friedreich ataxia [14].
MRI was mostly normal (10 patients), whereas 2
patients presented with cerebellar atrophy as can be
observed in advanced stages of the disease [15, 16]. These
patients were diagnosed after 9 and 3 years of disease
duration and the age at onset was respectively 20 and
13 years. One of the patients had vermian atrophy, with
an age at onset of 4 years and after 20 years of evolution.
Another patient showed a parieto-occipital atrophy, with
an onset at 27 years and a duration of the disease of 39 years.
One patient, with an an age at onset of 14 years and 9 years
of disease evolution, showed spinal cord atrophy.
In our cohort, 4 patients (15.4 %) with FXN mutations
had hypoacusia, as has already been reported in a similar
proportion [19, 20].
Electromyography (EMG) was normal in 2 patients,
while sensory motor polyneuropathy was found in 10,
sensory neuropathy in 8 and axonal neuropathy detected
in 2 other patients.
Cardiac impairment, frequent and usually correlated
to a premature death in Friedreich ataxia [15, 19, 21],
was noted in 7 patients.
None of the patients of our cohort had diabetes,
although it has been reported in approximately 10 % of
FRDA patients [16].
AVED patients
The second most common ARCA diagnosed was the
ataxia with isolated vitamin E deficiency (AVED), with
Table 3 Molecular findings in Algerian patients affected with autosomal recessive ataxia
ARCA (Gene) Number of patients (families) Family mutation (E, Exon. I, Intron) Reference
FRDA (FXN) 49 (31) Homo (GAA)n expansion (I1) [12]
AVED (TTPA) 19 (16) Homo c.744delA ; p.Glu249Asnfs*15 (E5) [11]
AOA2 (SETX) 2 (1) Homo c.2602C > T; p.Gln868* (E8) [32]
1 (1) Homo c.5267T > C ; p.Phe1756Ser (E8) [32]
9 (5) Homo del exon 17 and 18 [9]
1 (1) Homo del exon 5 [9]
1 (1) Homo c.5123G > C ; p.Trp1708Ser (E8) This study
1 (1) Homo c.5308_5311delGAGA ; p.Glu1770Ilefs*15 (E9) [64]
2 (1) Homo c.915G >T; p.Trp305Cys (E8) [32]
1 (1) Comp. Heter c.915G > T; p.Trp305Cys (E8) c.985C > T; p.Arg329* (E8) [32] This study
ARSACS (SACS) 1 (1) Homo c.7372_7376delCTTAT ; p.Leu2458Alafs*5 (E10) [65]
2 (1) Homo c.4882_4886delCAGTT/insAGAAGC p.Gln1628Thrfs*13 (10) [65]
4 (3) Homo c.12220G >C (exon 10), p.Ala4074Pro (E10) [36]
1 (1) Homo c.6355C >T (exon10); p.Arg2119* (E10) This study
AOA1 (APTX) 5 (3) Homo c.837G >A; p.Trp279* (E6) [44]
1 (1) Homo c.875-1G >A (disruption of splice site) (E7) [46]
SCAR9 (ADCK3) 4 (1) Homo c.1398 +2T>A; p.Asp420Trpfs*40/ p.Ile467Alafs*22 (I11) [49]
1 (1) Homo c.500_521delinsTTG, p.Gln167leufs*36 ( E3) [49]
1 (1) Homo c.1334_1335delCA ; p.Thr445Argfs*51 (E11) This study
PHARC (ABHD12) 1 (1) Homo c.846_852dupTAAGAGC; p.His285fs*1 (E9) [56]
SCAR8 (SYNE1) 1 (1) Homo c.3715G >T ; p.Glu1239* (E30) This study
MSS (SIL1) 1 (1) Homo c.1285T >G ; p.Tyr429Asp (E11) This study
AOA1, Ataxia with Oculomotor Aparaxia type 1; AOA2, Ataxia with Oculomotor Aparaxia type 2; ARCA, Autosomal Recessive Cerebellar Ataxia; ARSACS, Autosomal
Recessive Spastic Ataxia of Cherlevoix-Saguenay; AVED, Ataxia with isolated Vitamin E Deficiency; FRDA, Friedreich Ataxia; MSS, Marinesco-Sjögren syndrome;
PHARC, Polyneupathy, Hearing loss, Ataxia, Retinitis pigmentosa and Cataract; SCAR8, Spinocerebellar Ataxia, Autosomal Recessive 8; SCAR9, Spinocerebellar Ataxia,
Autosomal Recessive 9; Homo, homozygote; Comp. Heter, compound heterozygte
*Stop codon
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3 and 7 9.2 ± 3.7
SD (8-14)
12 and 16 7 birth
Initial signs
Gait limb ataxia 24 11 6 7 2 5 2 1 /
Dysarthria / / / / / / / / /
Head tremor 1 1 / / / / / / /
Muscle Weakness 1 / / / / 4 / / /
Cerebellar Syndrome
Mild / / / / / 5 / 1 /
Moderate 23 10 6 5 2 / 2 / /
Severe 3 2 6 3 / / / / 1
Head tremor 3 7 / / / 1 / / /
Dysarthria 23 12 5 7 2 3 1 1 1
Nystagmus 14 7 5 6 / / / / 1
Visual acuity decline 1 1 / 1 / / 1 / 1
Upper limbs tendon
reflexes
normal 5 2 / 3 / 1 / 1 /
weak 1 / 2 1 2 2 / / /
absent 15 10 4 / / / 2 / /
brisk 3 / / 3 / 1 / / 1
Lower limbs tendon
reflexes
normal 1 / / 3 / 1 / / /
weak / / 2 / 1 2 / / /
absent 19 12 4 / 1 / 2 1 /
brisk 4 / / 4 / 1 / / 1
Babinki sign 12 4 / 6 / / / / /
Dysmorphic syndrome
Scoliosis 19 9 3 1 1 1 / / /
Pes cavus 14 7 3 6 / 4 2 1 1
Flat feet / 3 / / / / / / /
Spasticity 3 1 / 6 / / / / 1
Cognitive impairment / / 1 2 2 2 / / /
MRI
normal 10 7 / 1 / 1 1 / /
cerebellar atrophy 2 1 6 1 1 3 1 / 1
vermian atrophy 1 3 4 1 1 / / /
not available 10 4 / 2 / / / 1 /
EMG
Normal 2 4 / 1 1 / / / /
SMP 10 4 3 4 / / 2 / /
SN 8 2 3 1 1 / / / /
AN 2 2 / / / / / / /
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19 patients (16 families) genetically confirmed: a unique
mutation (c.744delA) in the TTPA gene was found at a
homozygous state in all the patients, which further con-
firms its high frequency in the Mediterranen basin [22]
and its strong founder effect as suggested by Ouahchi
et al. [12] and supported by the recent report of El
Euch-Fayache et al., 2014 [23] or our personal data
(unpublished results).
Among our AVED patients, 12 (10 families) had under-
gone neurological examination and 8 patients (6 families)
were consanguineous.
The mean age at onset was 11 ± 4.69 SD years, ranging
from 4 to 17 years old, in accordance with the fact that
most of the patients already described have onset before
20 years old [22, 23].
All the patients but one (11) had gait-limb ataxia as a
first sign. Head tremor was the initial sign for the
remaining patient. Head titubation was noted in 7 out of
the 12 patients, a sign that could in fact be considered
significant to distinguish FRDA from AVED [23–25].
The upper limbs reflexes were abolished in 10 patients
and normal in 2, while the lower limb reflexes were
abolished in all the patients. These observations were ex-
pected as most AVED patients reported in the literature
have absent or weak tendon reflexes [24, 25].
Nystagmus was present in 7 patients and one patient
had a visual acuity decline. None of the Algerian patients
presented other ocular features such as retinitis pigment-
osa [26, 27] or oculomotor apraxia and exotropia [23].
Dysmorphic signs were either solely pes cavus (1 patient)
or scoliosis, which was associated with either pes cavus
(6 patients) or flat feet (3 patients).
In this cohort, MRI was normal in 7 patients, showed
the presence of cerebellar and vermian atrophy in one
patient and was not available for 4 patients. EMG results
were normal in 4 patients and abnormal in 8: two
patients had axonal neuropathy, four patients presented
with sensorimotor neuropathy and two patients displayed
purely sensory neuropathy. Although AVED is considered
to be an ataxia form presenting with a pure sensory neur-
opathy [14, 15, 28], patients with sensorimotor neuropathy
have in fact also been reported, particularly in a Tunisian
cohort [23].
All the patients carrying the c.744delA mutation in the
TTPA gene showed significantly low levels of vitamin E
in plasma, as initially stated by this biomarker for this
disease [22].
Although it has been reported that an early supple-
mentation with vitamin E can slow down the progres-
sion of the disease and maintain the walking capability
of the patients [29, 30], most of our patients received an
intermittent treatment, due to socioeconomic circum-
stances, making it difficult to assess the true course of the
disease and the real benefit of vitamin E supplementation.
One of our patients that had generalized tonico-clonic
seizures presented with early cerebellar syndrome, dysarth-
ria, abolished tendon reflexes, scoliosis and sensorimotor
neuropathy at 4 years of age, while cerebral computed
tomography was normal, as has been reported for a
Norway patient with vitamin E deficiency and epileptic
seizures but with compound heterozygous mutations in
the TTPA gene [31].
Table 4 Genotype/phenotype correlations in a group of patients of the Algerian cohort (Continued)
Cardiac impairment 7 / / / / / / / /
Epilepsy / 1 / 2 / / / / /
Hypoacusia 4 / / 2 / / 1 / /
AOA1, Ataxia with Oculomotor Aparaxia type 1; AOA2, Ataxia with Oculomotor Aparaxia type 2; ARCA, Autosomal Recessive Cerebellar Ataxia; ARSACS, Autosomal
Recessive Spastic Ataxia of Cherlevoix-Saguenay; AVED, Ataxia with isolated Vitamin E Deficiency; FRDA, Friedreich Ataxia; MSS, Marinesco-Sjögren syndrome;
PHARC, Polyneupathy, Hearing loss, Ataxia, Retinitis pigmentosa and Cataract; SCAR8, Spinocerebellar Ataxia, Autosomal Recessive 8 SCAR9, Spinocerebellar Ataxia,
Autosomal Recessive 9; /, absence of the sign (no patients)
Fig. 1 Patients of the Algerian cohort with identified forms of ARCA.
AOA1, Ataxia with oculomotor aparaxia type 1; AOA2, Ataxia with
oculomotor aparaxia type 2; ARSACS, Autosomal recessive spastic
ataxia of Cherlevoix-Saguenay; AVED, Ataxia with isolated vitamin E
deficiency; FRDA, Friedreich ataxia; MSS, Marinesco-Sjögren syndrome;
PHARC, Polyneupathy, hearing loss, ataxia, retinitis pigmentosa
and cataract; SCAR8, Spinocerebellar ataxia, autosomal recessive
8 (or ARCA1); SCAR9, Spinocerebellar ataxia, autosomal recessive
9 (or ARCA2)
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AOA2 patients
The third most frequent form of ataxia in our cohort
was the ataxia with oculomotor apraxia type 2 with
different mutations in the SETX gene. This cohort
included 18 patients (12 families) with AOA2, and this
study backs up the hypothesis already stated by Tazir
et al. [9] setting the AOA2 as the third most frequent
recessive ataxia in Algeria after FRDA and AVED.
Most of the mutations in our cohort have been previ-
ously described (Table 3). One mutation, c.5267 T > C ;
p.Phe1756Ser, previously found at a heterozygous state
in a patient from the United Kingdom [32] was found in
one of our patients at a homozygous state. All patients
but one were homozygous for the SETX mutations. This
patient was a compound heterozygote for a new muta-
tion c.985C > T; p.Arg329* associated with a previously
described mutation c.915G > T; Trp305Cys, both in exon
eight of the gene [9].
Out of the 18 patients with SETX mutations, 10
patients (6 families) have been previously reported [9],
while the remaining 8 (6 families) were newly diagnosed
patients. Out of the 18 patients, 8 (7 families) were con-
sanguineous, and out of the 8 newly diagnosed patients,
6 (4 families) were consanguineous and 6 (6 families)
had undergone a complete neurological examination.
The mean age at onset in our patients was 14.57 ± 3.87
SD years, ranging from 9 to 21 years old, in accordance
with the data of other published series of AOA2 patients
[9, 33–35].
The 8 newly diagnosed patients presented with cere-
bellar syndrome, dysarthria and nystagmus, as indicated
by the AOA2 phenotype that includes such features in
the great majority of the patients [9, 33, 34], whereas
only 2 of our patients had oculomotor apraxia, a sign
present in less than half of the patients [33, 34].
All patients had elevated alpha-fetoprotein levels
which is the main biological marker of AOA2 [32, 33].
Due to the significant size of the gene, only the pa-
tients with elevated AFP levels were therefore tested
for the presence of mutations in the SETX gene.
Although pes cavus and scoliosis are considered to be
occasional features [9, 33, 34], in our cohort, we could
observe 1 aptient with scoliosis only, 2 patients with
scoliosis and pes cavus, and 2 patients with pes cavus
only.
ARSACS patients
Our study suggests that ARSACS is the fourth most fre-
quent form of ataxia in Algeria, with 8 patients and 6
families.
We identified 4 different mutations in the SACS gene
in 8 patients. One of the mutations (c.6355C > T;
p.Arg2119*) was novel, and the mutation (c.12220G > C;
p.Ala4074Pro), previously described in Tunisian families
[36], was the most common mutation and was found in
4 patients (3 families).
All the patients with SACS mutations had undergone
neurological examination. The 8 patients (6 families)
were consanguineous.
The mean age at onset for our patients was 7.75 ± 4.62
SD years, ranging from 2 to 14 years old. Two patients
had onset at 12 years old and one at 14 years old, which
can be considered as late onset for ARSACS phenotype
[36, 37].
Dysarthria was present in 7 of our patients and was
acute for one of them, in accordance with one of the
major manifestations of the disease during the first two
decades of disease progression [37].
Although hyper myelinated retinal fibers has been con-
stantly described in Canadian ARSACS patients [38, 39],
we could notice their absence in all Algerian patients, as
has also been observed in Tunisian families [36].
Pyramidal signs were observed in our patients: Babinski
sign in 6 of our 8 patients; spasticity, either severe or
moderate, in 6 patients; upper and lower limbs reflexes,
brisk or very brisk, in 4 patients; while tendon reflexes
were normal in 3 patients, which could be explained by
the progression of peripheral neuropathy that thus mask
spasticity and pyramidal signs with the evolution of the
disease [37].
Cognitive impairment has been noted for two of the
patients of our cohort.
Two patients had epileptic seizures, a feature which
has been reported in a small proportion of patients
harboring SACS mutations [40, 41], while hearing loss, a
rare feature not mentioned in ARSACS patients, was
found in two of our patients.
A larger study of ARSACS is being conducted in
our population and will provide more insights on
this ataxia in our population, as the patients from
Algeria seems to share clinical phenotypes that can
be rather rare and can mislead the diagnosis (such
as later onset during the second decade, absence of
myelinated retinal fibers, epileptic seizures, mental
disability).
The huge size of the SACS gene complicates the screen-
ing of patients presenting atypical clinical phenotype and
indicates that this form of ataxia may be under-diagnosed
in several populations, including ours. The screening of
the gene is therefore worthwhile even when some features
are absent.
AOA1 patients
The ataxia with oculomotor apraxia type 1 (AOA1) was
the fifth most frequent ARCA in our cohort since we
have identified 6 patients (3 families) carrying APTX
mutations, although it seems to be a rare condition out-
side Japan or Portugal [42, 43].
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The nonsense mutation, c.837G >A; p.Trp279*, known
as the most frequent mutation in the European population
[44, 45], was present in 5 of our patients (2 families), while
one patient was homozygous for a splice mutation on the
acceptor splice site of exon 7, c.875-1G > A.
A consanguineous context was noted in 5 patients
(4 families) and two of these patients (from two unrelated
families) had undergone neurological examination.
The age at onset in our patients was 3 and 7 years old
respectively, with gait-limb ataxia as a first sign for both
patients, accordingly with the early-onset status of this
form of ataxia [42, 46, 47].
Our patients had moderate cerebellar syndrome with
dysarthria, but absence of nystagmus although this later
feature accounts for one of the main clinical signs of
AOA1 [42]. However, both patients had oculomotor
apraxia and one of them presented with sensory neur-
opathy. Our two AOA1 patients had cognitive impair-
ment, which was acute for one of them. This feature,
initially thought to be exclusive to Japanese patients
[43], was nevertheless found in a cohort of Italian
patients [47] and is here described for the second time
in non-Japanese patients.
MRI showed in our patients a severe cerebellar atro-
phy in one case and a severe vermian atrophy in the
other, as has been reported in all affected AOA1 patients
[42, 47, 48].
SCAR9 patients
The report of a new case of SCAR9 in Algeria in this
study, after the identification of the causal gene in two
Algerian families [49], brings the number of patients
with genetically confirmed SCAR9 to 6 (3 families) in
Algeria and to 24 worldwide [49–51].
The patient we report here carried a novel frameshift
mutation c.1334_1335delCA, p.Thr445Argfs*51 in the
ADCK3 gene, highlighting that all the mutations identi-
fied so far in Algeria are truncating.
Although the delineation of the SCAR9 phenotype
remains difficult because of the great clinical differences
from one patient to another [51], the clinical features of
all the SCAR9 Algerian patients seems relatively similar.
In fact, this new patient was diagnosed after 2 years of
disease duration and shared with the other Algerian
patients already described a similar age at onset (8 years
old/mean onset age of 6.8 ± 2.95 SD years, ranging from
4 to 11 years old) and a very mild cerebellar syndrome
with gait limb ataxia and muscle weakness as first signs.
The upper and lower limb reflexes were weak for 2
patients including the newly reported one but were
either brisk or normal for the others. All patients had
dysarthria and pes cavus but only the patient carrying
the newly found mutation presented with mild scoliosis.
The MRI showed no abnormalities for this patient,
which can be explained by the early diagnosis and the
short time of disease duration. All the other patients
(with 14 to over 30 years of disease duration) showed
cerebellar atrophy.
Our patient should also be surveyed for signs of inte-
lectual deficiency as mild forms have been observed in
two of the Algerian patients and was reported as mild,
moderate or severe in non-Algerian patients [49–52].
All the Algerian patients with SCAR9 seems to have a
mild, slowly progressive or even stable cerebellar ataxia,
which was suggested as a main feature for SCAR9 pheno-
type, in contrast with most of childhood-onset ARCA
[50–52]. The existence of severe SCAR9 phenotypes can
however be observed, probably explained by the occur-
rence of stroke-like episodes or severe progressive enceph-
alopathy including cerebellar atrophy [51, 53].
PHARC patients
Our cohort of 6 patients included 2 of the siblings previ-
ously described in studies of PHARC and which allowed
the identification of the gene, showing that all reported
mutations so far results in premature stop codons pre-
sumed to cause a loss of function of the protein [54, 55].
All Algerian patients had thus the same homozygous
mutation c.852insTAAGAGC (c.846_852dupTAAGAGC);
p.His285fs1*. In our study, we screened the ABHD12 gene
for two Algerian patients who presented a phenotype
somewhat similar to the Algerian patients identified in the
report of Fiskerstrand et al. [56]. The two previously
reported Algerian patients and included in our cohort had
onset at 12 and 18 years of age respectively, had both
cerebellar ataxia and peripheral neuropathy; one had an
important decline in visual acuity and the other presented
with cataract. However, the two new patients we explored
did not carry ABHD12 mutations. Although our criteria
were mainly the presence of ataxia and polyneuropathy
associated with either cataract, a decline in visual acuity
and/or hearing loss, it could not exclude the presence of
atypical clinical presentations, as was the case for non-
Algerian PHARC patients. Indeed, neither signs of
polyneuropathy nor ataxia were observed in these siblings,
while their hearing loss and cataract were wrongly attrib-
uted to their age or the progression of the retinitis pig-
mentosa, thereby expanding the phenotypical spectrum of
PHARC [55]. We can however assume that this syndrome
could be in fact extremely rare.
SCAR8 patient
We identified in the present cohort a patient carrying a
novel mutation, c.3715G > T; p.Glu1239*, in the SYNE1
gene, thereby reporting the first Algerian patient with a
genetically confirmed recessive ataxia SCAR8.
The patient had consanguineous parents and 10 siblings
who were all healthy. The age at onset was 7 years old,
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which can be considered as early-onset in contrast to the
findings in the French-Canadian patients who showed a
middle-aged onset [57, 58]. The patient had gait limb
ataxia as a first sign and presented with mild cerebellar
syndrome and dysarthria; she had normal upper limb re-
flexes but abolished lower ones. The identification of the
causal mutation was performed by targeted genomic cap-
ture shortly after the first consulting, while MRI and EMG
examinations were not done. It would therefore be inter-
esting to see if this patient has a marked diffuse cerebellar
atrophy and no signs of neuropathy, as was shown in the
French-Canadian patients [57, 59]. The phenotypic fea-
tures of our patient showed that the outlines of the disease
remain ambiguous, with probable great variability in pa-
tients outside Quebec and Canada. It also indicates that
unrecognized features, such as early onset, may lead to
the underdiagnosis of this form of ataxia, particularly be-
cause genetic analysis faces such a large gene as SYNE1
with its 145 coding exons and complicates considerably
the mutational screening.
MSS patient
We report in this study the first genetically confirmed
case of Algerian patient with Marinesco-Sjögren syndrome
(MSS) and the characterization of a new mutation in the
SIL1 gene, c.1285 T >G; p.Tyr429Asp, at the homozygous
state.
This patient had consanguineous parents and had an
initial psychomotor impairment that started at birth
(sitting position acquired at 2 years and a half, walking
without help never acquired, and speech acquisition at
4 years old with an important dysarthria). The patient
was 14 years old when diagnosed and had severe
cerebellar syndrome (walk without bilateral help was
impossible), severe dysarthria, nystagmus and visual acuity
decline. The upper and lower limbs reflexes were brisk
and the patient presented a mild spasticity but no Babinski
sign. Dysmorphic features consisted in pes cavus and cra-
niofacial dysmorphy. MRI showed cerebellar atrophy and
hypoplasia. The patient had congenital cataract, but has
undergone surgery at 6 years of age. Once the molecular
diagnosis established, the patient was also found to have
hypergonadotropic hypogonadism, in accordance with
the presentation of the syndrome [60, 61].
Although MSS patients have been reported in many
countries [60, 62, 63], there is no epidemiological data on
the occurrence of this syndrome. Targeted genomic cap-
ture and massive parallel sequencing could therefore help
to screen for such genes described in rare syndromes.
Conclusions
We report with this large cohort of genetically deter-
mined autosomal recessive ataxia, the first study of the
genetic context of ARCA in Algeria. Our study shows
that, in addition to the most common mutations and
ataxias, other rarer or underdiagnosed forms might be
involved and could be underestimated. Taken together,
FRDA and AVED patients thus represented 61.82 % of
the patients in this cohort (68 patients) while combined,
FRDA, AVED, AOA2, ARSACS and AOA1 accounted
for 90.9 % of the cohort (100 patients) of the whole
autosomal recessive forms of ataxia in our cohort.
Besides these most frequent forms, we were able to iden-
tify other types of ataxia seemingly rare in our population.
A precise assessment of the frequent forms and muta-
tions specific to our population can strongly help the
orientation of the investigations in the long term. How-
ever, for rare and heterogeneous pathologies as auto-
somal recessive ataxia, there is still a long way to go in
order to refine genotype/phenotype correlations. More
extensive molecular and epidemiological investigations
will allow a better knowledge of the different ARCA and
facilitate the genetic explorations. The power of innova-
tive approaches, such as high-throughput sequencing,
opens now new perspectives for diagnosis and research
and will certainly provide mandatory answers for patients
remaining without molecular diagnosis.
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